Abstract Library

#4468 Prevalence of familial pheochromocytoma and paraganglioma syndromes – A large multicentre study

Introduction: Pheochromocytoma and paraganglioma (PPGLs) are rare tumours. Depending on the studied population, approximately 30% of PPGLs are caused by a germline pathogenic variant (PV).

Conference:

Presenting Author: Halperin R

Authors: Halperin R, Reznick-Levi G, Khalaileh A, Svirsky-Frayden R, Reish O,

Keywords: paraganglioma, pheochromocytoma, genetic evaluation, catecholamine, sdhb, vhl,

#4340 Predominant volumetric phenotype in dual PET and overall survival in NENs

Introduction: Dual 18F-FDG/68Ga-DOTATATE PET can predict NEN prognosis and guide treatment choice. However, research to date (such as the NEPTET score) has focused on the dual PET phenotype of single-point lesions rather than of the total disease volume.

Conference:

Presenting Author: Chan D

Authors: Chan D, Bernard E, Mokhtar S, Chou A, Gill A,

Keywords: Prognostic biomarker, PET/CT, tumour volume, 18F-FDG, 68Ga-DOTATATE,

#4074 Clinical, genetic and histopathological characterisation of patients with multiple endocrine neoplasia type 1 in two high complexity hospitals in Medellín, Colombia

Introduction: Limited observational data exist regarding the characterization of patients with Multiple Endocrine Neoplasia Type 1 (MEN-1) in Latin America, particularly in Colombia. This scarcity has led to a reliance on studies that may not precisely depict the actual behaviour of the disease within the population.

Conference:

Presenting Author:

Authors: Roman-Gonzalez A, Gil-Gonzalez M, Pérez-Giraldo E, Agredo Delgado V, Lopez-Montoya V,

Keywords: multiple endocrine neoplasia type 1, neuroendocrine tumor, acromegaly, cushing disease, hyperparathyroidism,

#3853 Determining the resistance to somatostatin analogues in pheochromocytomas and paragangliomas

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) derived from chromaffin cells of the neural crest. Somatostatin analogues (SSAs) represent one of the pillars for NENs diagnosis/treatment due to the high density of somatostatin receptor (SSTs) in their membrane. However, although PPGLs share this characteristic, their response to SSAs is limited, being the reason underlying this unresponsiveness still unknown.

Conference:

Presenting Author:

Authors: García Vioque V, Blázquez-Encinas R, Moreno Montilla M, Mangili F, Martínez Montes �,

Keywords: pheochromocytoma, paraganglioma, neuroendocrine tumor, somatostatin analogues, treatment resistance,

#3852 Novel insights to study the potential of the somatostatin system in NETs and NECs

Introduction: Neuroendocrine tumors (NETs) and carcinomas (NECs) are a heterogeneous group of cancers with increasing incidence worldwide. Surgery is the only curative choice, whereas an effective pharmacological approach for disseminated disease is still lacking. Somatostatin (SS) receptors (SSTs) provide a suitable pharmacological target to treat NETs with SS analogues (SSAs). However, a large proportion of NETs and, particularly most NECs, are unresponsive or resistant to SSAs. The underlying causes remain poorly understood and alternative strategies are needed. Recently, cortistatin (CST), a neuropeptide analogue of SS with comparable affinity to SSTs, emerged as an anti-inflammatory player, with potential antitumoral features.

Conference:

Presenting Author: Mangili F

Authors: Mangili F, Moreno Montilla M, García Vioque V, Blázquez-Encinas R, Mantovani G,

Keywords: PanNET, PanNEC, Somatostatin receptor (SST), cortistatin, Somatostatin,